Skip to content

A gradual release of Avioverse begins in October 2026. Request early access →

MED.B.090 Oncology

ANNEX IV (Part-MED) · Regulation (EU) No 1178/2011 · EAR revision 25 Nov 2025

IRImplementing rule

MED.B.090Oncology

(a)Before further consideration is given to their application, applicants with primary or secondary malignant disease shall undergo satisfactory oncological evaluation. Such applicants for a class 1 medical certificate shall be referred to the medical assessor of the licensing authority. Such applicants for a class 2 medical certificate shall be assessed in consultation with the medical assessor of the licensing authority.

(b)Applicants with a documented medical history or clinical diagnosis of an intracerebral malignant tumour shall be assessed as unfit.

IR · MED.B.090 — Regulation (EU) No 1178/2011 · Regulation (EU) 2019/27 · Aircrew Easy Access Rules · EAR revision 25 Nov 2025

AMCAcceptable means of compliance

AMC1 MED.B.090Oncology

Show the text

(a)Applicants who have been diagnosed with a malignant disease may be assessed as fit provided that:

(1)after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2)time appropriate to the type of tumour and primary treatment has elapsed;

(3)the risk of inflight incapacitation from a recurrence or metastasis is sufficiently low;

(4)there is no evidence of short or long-term sequelae from treatment. Special attention should be paid to applicants who have received anthracycline chemotherapy;

(5)satisfactory oncology follow-up reports are provided to the medical assessor of the licensing authority.

(b)An OML should be applied as appropriate.

(c)Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(d)Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is regular follow-up.

AMC · AMC1 MED.B.090 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 25 Nov 2025

AMCAcceptable means of compliance

AMC2 MED.B.090Oncology

Show the text

(a)Applicants who have been diagnosed with a malignant disease may be considered for a fit assessment provided that:

(1)after primary treatment, there is no evidence of residual malignant disease likely to jeopardise flight safety;

(2)time appropriate to the type of tumour and primary treatment has elapsed;

(3)the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;

(4)there is no evidence of short or long-term sequelae from treatment that may jeopardise flight safety;

(5)arrangements for an oncological follow-up have been made for an appropriate period of time.

(b)Applicants receiving ongoing chemotherapy or radiation treatment should be assessed as unfit.

(c)Applicants with pre-malignant conditions of the skin may be assessed as fit if treated or excised as necessary and there is a regular follow-up.

AMC · AMC2 MED.B.090 — Regulation (EU) No 1178/2011 · ED Decision 2019/002/R · Aircrew Easy Access Rules · EAR revision 25 Nov 2025

All rules in SUBPART B – REQUIREMENTS FOR PILOT MEDICAL CERTIFICATES

Consolidated from the EASA Easy Access Rules (revision 25 Nov 2025, extracted 17 Aug 2026) for convenience. Not the official publication — verify against the Official Journal of the European Union and the EASA publications before operational use.

Ask Metis about MED.B.090 →

Metis opens with Avioverse in October 2026 · request early access.